Research programme: prostaglandin mimetics - York PharmaAlternative Names: Respiratory antiviral programme - York Pharma; RPL 208
Latest Information Update: 04 Apr 2011
At a glance
- Originator York Pharma
- Mechanism of Action Prostaglandin agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Viral infections
Most Recent Events
- 13 Jun 2007 Preclinical trials in Viral infections in United Kingdom (unspecified route)
- 13 Jun 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)